Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality After Elective Cesarean Section

29. Oktober 2026 aktualisiert von: Li Juan, Anhui Provincial Hospital

Effects of Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality in Parturients Undergoing Cesarean Section: a Prospective Randomized Controlled Trial

This study is a prospective randomized controlled trial aimed at evaluating whether the combination of esketamine and transcutaneous electrical acupoint stimulation (TEAS) can improve the quality of postoperative recovery in women undergoing elective cesarean section. First-time mothers scheduled for surgery will be randomly assigned to one of four groups: a control group (standard care), a TEAS group, an esketamine group, or a combined group (TEAS plus esketamine). TEAS will be applied to specific acupoints before delivery. Esketamine (0.15 mg/kg) will be administered intravenously immediately after the umbilical cord is clamped to minimize fetal exposure. The primary outcome is the overall quality of recovery, assessed using the ObsQoR-11 scale during the first three days after surgery. We will also evaluate pain levels, sleep quality, anxiety and depression, early recovery milestones, inflammatory responses, adverse reactions, and newborn safety. The results may provide an effective multi-modal strategy to enhance recovery for mothers after a cesarean delivery.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background and Rationale:

Cesarean section is one of the most common obstetric surgeries globally. Inadequate postoperative pain management can negatively impact maternal sleep, early ambulation, breastfeeding, and increase the risk of postpartum anxiety and depression. Esketamine, an NMDA receptor antagonist, provides effective analgesia, opioid-sparing effects, and mood regulation. Transcutaneous electrical acupoint stimulation (TEAS) is a non-invasive neuromodulation technique that exerts analgesic effects through the endogenous opioid system and regulates gastrointestinal function. The clinical benefits of esketamine and TEAS are complementary, suggesting a potential synergistic effect in multimodal analgesia and enhanced recovery after surgery (ERAS).

Specific Study Design Rationale:

The acupoints selected in this trial (PC6, HT7, and LI4) are specifically targeted for their effects on pain relief, anxiolysis, and gastrointestinal motility. A disperse-dense frequency (2/10 Hz) is utilized to prevent nerve adaptation and maximize tolerance. Furthermore, to minimize fetal exposure, esketamine will be administered intravenously only after fetal delivery and umbilical cord clamping.

Significance:

This study aims to translate the theoretical synergistic benefits of these two interventions into clinical evidence. The findings will determine whether this combined strategy offers incremental benefits over single interventions in improving the overall quality of recovery for parturients, thereby providing a robust clinical basis for optimizing multimodal analgesic and ERAS protocols.

Studientyp

Interventionell

Einschreibung (Geschätzt)

384

Phase

  • Unzutreffend

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 99 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

- Age ≥ 18 years. (No upper age limit).

Primiparous women.

American Society of Anesthesiologists (ASA) physical status I or II.

Gestational age between 37 and 42 weeks.

Scheduled for elective cesarean section under epidural anesthesia.

Exclusion Criteria:

- History of allergy or contraindication to esketamine.

Contraindications to neuraxial anesthesia (e.g., coagulopathy).

Severe pregnancy complications (e.g., severe fetal distress, umbilical cord prolapse, placenta previa with massive hemorrhage, placental abruption).

Severe dysfunction of vital organs.

Skin breakdown or infection at the selected acupoint sites.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Control Group

Participants receive sham TEAS (device turned off) and an intravenous injection of 10 mL normal saline after umbilical cord clamping.

10 mL of 0.9% normal saline administered intravenously as a placebo immediately after umbilical cord clamping.

The TEAS device is applied to the same acupoints but with the electrical current turned off (the light flashes to blind the participant).

Experimental: TEAS Group

Participants receive active TEAS at PC6, HT7, and LI4 acupoints, and an intravenous injection of 10 mL normal saline after umbilical cord clamping.

10 mL of 0.9% normal saline administered intravenously as a placebo immediately after umbilical cord clamping.

Applied bilaterally at PC6 (Neiguan), HT7 (Shenmen), and LI4 (Hegu) acupoints using a Hwato DZ-III stimulator. Parameters: disperse-dense frequency of 2/10 Hz, intensity adjusted to the maximum tolerable level (6-12 mA).

Experimental: Esketamine Group

Participants receive sham TEAS and an intravenous injection of 0.15 mg/kg esketamine (diluted in 10 mL normal saline) after umbilical cord clamping.

The TEAS device is applied to the same acupoints but with the electrical current turned off (the light flashes to blind the participant).

Administered intravenously at a dose of 0.15 mg/kg (diluted in 10 mL normal saline) immediately after umbilical cord clamping.

Experimental: Combined Group

Participants receive active TEAS and an intravenous injection of 0.15 mg/kg esketamine (diluted in 10 mL normal saline) after umbilical cord clamping.

Applied bilaterally at PC6 (Neiguan), HT7 (Shenmen), and LI4 (Hegu) acupoints using a Hwato DZ-III stimulator. Parameters: disperse-dense frequency of 2/10 Hz, intensity adjusted to the maximum tolerable level (6-12 mA).

Administered intravenously at a dose of 0.15 mg/kg (diluted in 10 mL normal saline) immediately after umbilical cord clamping.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Quality of Postoperative Recovery
Zeitfenster: Postoperative days 1, 2, and 3.

Assessed using the ObsQoR-11 (Obstetric Quality of Recovery-11) scale. The score ranges from 0 to 110, with higher scores indicating better quality of recovery.

Postoperative days 1, 2, and 3.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Postoperative Pain and Sedation
Zeitfenster: 12, 24, and 48 hours postoperatively (for VAS and PCA); perioperative period (for sedation).

Visual Analogue Scale (VAS) scores at rest and during movement (0 = no pain, 10 = worst pain); consumption and effective presses of patient-controlled analgesia (PCA); requirement for rescue analgesics (Flurbiprofen axetil); and Ramsay sedation scores.

12, 24, and 48 hours postoperatively (for VAS and PCA); perioperative period (for sedation).
Sleep Quality and Psychological Status
Zeitfenster: 1 month preoperatively, postoperative days 1-2, and 1 month postoperatively.

Pittsburgh Sleep Quality Index (PSQI) for preoperative sleep; Leeds Sleep Evaluation Questionnaire (LSEQ) for postoperative sleep; Hospital Anxiety and Depression Scale (HADS); and Edinburgh Postnatal Depression Scale (EPDS).

1 month preoperatively, postoperative days 1-2, and 1 month postoperatively.
Perioperative Hemodynamic Parameters
Zeitfenster: Baseline, after block reaches T6-S, skin incision, 1 and 5 minutes after study drug injection, fetal delivery, end of surgery, and 1 and 2 hours postoperatively.

Heart Rate (HR), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Mean Arterial Pressure (MAP).

Baseline, after block reaches T6-S, skin incision, 1 and 5 minutes after study drug injection, fetal delivery, end of surgery, and 1 and 2 hours postoperatively.
Early Recovery Milestones and Perioperative Data
Zeitfenster: From surgery to hospital discharge.

Time to first flatus, first urination, first ambulation, and urinary catheter removal; length of hospital stay; surgical duration; intraoperative blood loss, urine output, and fluid infusion volume.

From surgery to hospital discharge.
Inflammatory Markers
Zeitfenster: baseline and on postoperative day 2.

White Blood Cell (WBC) count, Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR).

baseline and on postoperative day 2.
Maternal Adverse Events and Neonatal Outcomes
Zeitfenster: Intraoperative and postoperative days 1-3 (for maternal outcomes); immediately after delivery (for neonatal outcomes).

Incidence of maternal adverse reactions (e.g., nausea, vomiting, dizziness, hallucinations, skin allergies, respiratory depression); neonatal Apgar scores at 1 and 5 minutes; umbilical cord blood gas analysis (pH, Base Excess, lactate); and NICU admission rate.

Intraoperative and postoperative days 1-3 (for maternal outcomes); immediately after delivery (for neonatal outcomes).

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. Oktober 2026

Primärer Abschluss (Geschätzt)

30. Oktober 2027

Studienabschluss (Geschätzt)

30. Oktober 2027

Studienanmeldedaten

Zuerst eingereicht

29. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Oktober 2026

Zuerst gepostet (Tatsächlich)

4. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2026KY498

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be shared due to patient privacy and ethical restrictions. The data contains sensitive maternal and neonatal health information, and the informed consent obtained from participants does not permit public data sharing.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .